PRTN3 and rheumatoid arthritis: With the aim of improving the uncertainties associated with the correct diagnosis of seronegative RA patients and those at risk of developing ILD, we designed novel peptide antigens (Figure 1) bearing three post-translational modifications (citrulline, homocitrulline and acetyl-lysine) related to this disease that could complement existing ACPA-based tests.